EyePoint Pharmaceuticals and Vision Center Network of America (VCNA) have entered into a purchase agreement for DEXYCU® (dexamethasone intraocular suspension) 9% for its network of nine surgery centers located in New York and New Jersey that perform an estimated 60,000 cataract procedures annually. The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.
“We look forward to working with VCNA to further broaden DEXYCU’s commercial reach in the United States and to improve the care for patients by providing an effective therapy for treating inflammation associated with cataract surgery. VCNA is a fast-growing network and we look forward to being their preferred partner,” Nancy Lurker, President and Chief Executive Officer of EyePoint said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
“We are delighted that Eyepoint Pharmaceuticals has decided to enter into a relationship with VCNA. Given the high volume of cataract surgeries performed annually across our centers, we believe that this agreement will enhance the value proposition we offer to our patients and payers,” Dr. Jerome Levy, President and Chairman of the Board at VCNA said.